

Ref: FOI/GS/ID 6159

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

26 June 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Cancer treatments.

You asked:

1. In the past 3 months, how many metastatic melanoma patients were treated by your Trust?

- a. Dabrafenib*
- b. Dabrafenib + Trametinib*
- c. Densoumab*
- d. Encorafenib + Binimetinib*
- e. Ipilimumab*
- f. Ipilimumab + Nivolumab*
- g. Nivolumab*
- h. Pembrolizumab*
- i. Trametinib*
- j. Vemurafenib*
- k. Vemurafenib + Cobimetinib*
- l. Other active systemic anti-cancer therapy*

Palliative care only

2. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:

- a. Afatinib*
- b. Atezolizumab monotherapy or combination*
- c. Brigatinib*
- d. Ceretinib*
- e. Crizotinib*
- f. Docetaxel monotherapy or combination*
- g. Erlotinib*
- h. Gefitinib*

- i. Gemcitabine
- j. Nitendanib + docetaxel
- k. Nivolumab
- l. Osimertinib
- m. Paclitaxel
- n. Pembrolizumab monotherapy
- o. Pembrolizumab chemo in combination
- p. Pembrolizumab monotherapy
- q. Pemetrexed monotherapy or combination
- r. Ramucirumab
- s. Vinorelbine monotherapy or combination
- t. Other active systemic anti-cancer therapy
- u. Palliative care only

3. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC) with the following products?

- a. Afatinib
- b. Atezolizumab monotherapy or combination
- c. Brigatinib
- d. Ceretinib
- e. Crizotinib
- f. Docetaxel monotherapy or combination
- g. Erlotinib
- h. Gefitinib
- i. Gemcitabine
- j. Nitendanib + docetaxel
- k. Nivolumab
- l. Osimertinib
- m. Paclitaxel
- n. Pembrolizumab monotherapy
- o. Pembrolizumab chemo in combination
- p. Pembrolizumab monotherapy
- q. Pemetrexed monotherapy or combination
- r. Ramucirumab
- s. Vinorelbine mono or combination
- t. Other active systemic anti-cancer therapy
- u. Palliative care only

Trust response:

- 1.
- a. 0
- b. 15
- c. 0
- d. 1
- e. 1
- f. 5
- g. 11
- h. 53
- i. 0

- j. 1
- k. 0
- l. 8
- m. Unable to provide
- 2.
- a. 18
- b. 8
- c. 3
- d. 0
- e. 3
- f. 0
- g. 1
- h. 1
- i. 1
- j. 0
- k. 0
- l. 8
- m. 1
- n. 15
- o. 8
- p. 0
- q. 24
- r. 0
- s. 22
- t. 83
- u. Unable to provide

3. Pharmacy are not able to determine whether these patients have Squamous or non-squamous disease based on which drugs they receive as a lot of these drugs are used in both and it is not specified in the regimen. The Trust would need to examine each patient record in order to gather this information. The Trust has estimated that it will cost more than the appropriate limit to consider this part of your request. The appropriate limit is specified in regulations and represents the estimated cost of one person spending 3½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act 2000 the Trust is not obliged to comply with this part of your request and we will not be processing this part of your request further.